|Articles|June 1, 2006
- Special Issues-07-01-2006
- Volume 0
- Issue 0
Validation in Biotechnology and Well-Characterized Biopharmaceutical Products
This article describes the current situation in FDA-regulated areas, as well as characterization of these products. Finally,the author discusses the various stages of early- and late-phase product developments.
Advertisement
Articles in this issue
over 20 years ago
Analytical Instrument Qualificationover 20 years ago
GMP and Phase I Clinical Trials: Streamlining the Critical Path?over 20 years ago
Team Effortover 20 years ago
Rated PG: Pharmaceutical Guidance Suggestedover 20 years ago
European Clinical Trial Regulations Undergo a Slow Revolutionover 20 years ago
Moving Biotech Products from CBER to CDER: A Work in Progressover 20 years ago
New Climateover 20 years ago
2006: A Regulatory OdysseyAdvertisement
Related to this article
Advertisement
Advertisement
Trending on LCGC International
1
GC–MS Probes Acidity and Heat in Wasabi, Mustard
2
HPLC–DAD Method Tracks Semaglutide and Tirzepatide Stability
3
GLP-1 Peptide Analysis: Challenges and Solutions
4
AI/ML Now: Uncertainty-Driven Model-Based Search Methods for Method Development in Liquid Chromatography (Part Two)
5